Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. - Wikidata - wikimedia - TriplyDB

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.

http://www.wikidata.org/entity/Q36759382

about

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives Non-invasive metabolic imaging of brain tumours in the era of precision medicine.Detection of 2-hydroxyglutarate in brain tumors by triple-refocusing MR spectroscopy at 3T in vivo.Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma Advances in neuro-oncology imaging.Controversies in management of low-grade gliomas in light of new data from clinical trials.An Update on the Approach to the Imaging of Brain Tumors.Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.Imaging Tumor Metabolism to Assess Disease Progression and Treatment Response.Altered metabolite levels in cancer: implications for tumour biology and cancer therapy.New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives.Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas.Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy.Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy.IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas: Advances in Surgical Strategy.Diagnostic Accuracy of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy in Newly-Diagnosed Brain Mass and Suspected Recurrent Gliomas.[Metabolome analysis of solid tumors].Conventional and advanced magnetic resonance imaging in patients with high grade glioma.Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.Imaging in neuro-oncology.Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.

P2860

Q28066926-A003AA59-2D55-4A39-A506-4FB810CACB49 Q31115540-DDC2716A-1A2E-41E6-AEA4-B3A2BA98A5E2 Q31117278-0C830B11-1CED-45A6-A701-E29ADD3613F4 Q33816600-7655EA51-3BE9-4209-A5DE-1B98BF8FE3E2 Q36339461-9634A8AA-4325-44AE-9D2B-A9AE3576C55E Q36341111-332B9135-7657-4A38-9C0D-4A8124F42B3F Q36374577-A55EFF1B-D372-42BE-B90E-739886DED017 Q36805635-CC4EE48C-53DA-497A-B05B-F23FB0FAE0A0 Q38612062-B7778AF9-5685-4501-BCC2-D62AC280BCCB Q38949887-CC32E999-AC63-4332-8B1A-7EAB069EF996 Q38961789-6EA0C5A8-FC18-497F-A18E-514B43D13766 Q39167472-00431EC2-6011-429A-9FD1-8C75A5B28C1D Q39312420-BAA07171-80E5-44C3-B36F-60FA3EDFF248 Q39383501-ADB57374-9771-4CB2-B04A-4D8C024937A8 Q42702320-B5A3EC54-8BD4-42E7-ADC5-76547CC6CE6F Q42702324-C6C90A43-3CF3-4E71-89EC-2693D86AEE95 Q47605895-53866C0C-4E35-48DA-80FE-F90EAF973369 Q47617473-A950FADE-A63D-42AF-9245-702DFBC7F915 Q48093789-AC52B2AE-4EA7-4599-AD16-8E6288E1A39D Q48663479-96E457D5-81F6-4E74-B430-180D86E68934 Q50041501-287CCC21-4B8D-41FD-B268-8EACB9F58345 Q51806041-EB46DC9E-A68D-4B04-B626-20FAD4DB3C53 Q52562075-CC890820-E8E6-40F2-9CDA-EE0111203829 Q52584624-D1FCF935-2326-4CF0-8BEE-92E42F54E54D Q54973707-EB226AA2-3268-4306-B1E8-927760C4F91B Q55457298-FE82B854-4E0F-46B0-8E44-0183A8E94EAC

P2860

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.

http://www.wikidata.org/entity/Q36759382

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Treatment Response Assessment ...... Mapping of 2-Hydroxyglutarate.

@ast

Treatment Response Assessment ...... Mapping of 2-Hydroxyglutarate.

@en

type

label

Treatment Response Assessment ...... Mapping of 2-Hydroxyglutarate.

@ast

Treatment Response Assessment ...... Mapping of 2-Hydroxyglutarate.

@en

prefLabel

Treatment Response Assessment ...... Mapping of 2-Hydroxyglutarate.

@ast

Treatment Response Assessment ...... Mapping of 2-Hydroxyglutarate.

@en

P1433

Q36759382-044585E7-8749-4D59-82C5-59660FFA002A

P1476

Q36759382-156C2F60-6FDA-4823-843E-FD9B59C868ED

P2093

Q36759382-5980A068-34C3-4E4D-917F-BAA5C128BD7C

Q36759382-5FA3626C-4FDB-4596-BBC0-ECB372E1F912

Q36759382-683774D6-CC12-4413-B254-CB35F8C6498D

Q36759382-79515B4C-E92D-4D58-A1E4-3E8289DA6812

Q36759382-819BC0DD-7F74-4014-B603-5D84F9B471DB

Q36759382-88E12A47-60AA-48CB-B430-836BA8DAAA14

Q36759382-91715D18-1FD5-4535-A56B-8080B2592B39

Q36759382-9EE8DF6F-78E2-4AD7-8A1F-D96453870578

Q36759382-A9A2278A-F6E5-445D-9EF8-AE0DD906C3B3

Q36759382-D69DCF17-276C-4379-AF25-8C664F45647D

P2860

Q36759382-0543A414-2A8B-4F6A-A8A6-24725E502285

Q36759382-077A99B2-0642-498F-8A8D-EC2C09B8D83A

Q36759382-0F91504D-78CF-4C0B-B5DB-62CCF4BED808

Q36759382-1AC09F58-CB49-4591-8739-5898B144DAEC

Q36759382-1E5B6A6E-E583-4143-9133-55A904647563

Q36759382-2AC094A3-463C-422E-B7D8-A034F8D4425C

Q36759382-3CFA4E18-3FE5-4341-84F6-2373A419F7C6

Q36759382-3E57A9BE-A808-4185-8BF4-20716A5D1A4A

Q36759382-405297FF-3632-4ECD-A77C-A2F81152E741

Q36759382-41256D40-8BF7-4863-9707-B6CC14579F7F

P304

Q36759382-27396BC7-97AD-4B9C-8A34-B7571A4B432E

P31

Q36759382-571C4F4F-DE6C-4002-83F7-34D2B3398743

P356

Q36759382-AEFB1B46-ACCC-4E19-A1EF-A151A7FF20B4

P407

Q36759382-F73E8A3C-A4AC-43F2-BB6B-7BEB143B3C34

P433

Q36759382-81743DC5-B74E-4830-B0C3-7558F39B8BED

P478

Q36759382-6AFF49D0-262F-41DA-A254-DABF3C322DB4

P50

Q36759382-C33DA2F6-CC01-4012-AFAE-25E5EE80E59C

Q36759382-CD6C62F8-039C-4B1E-B858-1A2849F4E053

P577

Q36759382-05646A75-4898-4110-B82B-166A5789E3BA

P698

Q36759382-F4E732C3-AB58-456A-AC84-C71000B4B6EC

P932

Q36759382-EBEA1131-EB9D-4476-B5C3-BF49C2B7F93D

P356

1078-0432.CCR-15-0656

P1433

Clinical Cancer Research

P1476

Treatment Response Assessment ...... Mapping of 2-Hydroxyglutarate

@en

P2093

A John Iafrate

http://www.w3.org/2001/XMLSchema#string

Andrew S Chi

http://www.w3.org/2001/XMLSchema#string

Bruce R Rosen

http://www.w3.org/2001/XMLSchema#string

Elizabeth R Gerstner

http://www.w3.org/2001/XMLSchema#string

Franziska Loebel

http://www.w3.org/2001/XMLSchema#string

Jorg Dietrich

http://www.w3.org/2001/XMLSchema#string

Matthew G Vander Heiden

http://www.w3.org/2001/XMLSchema#string

Małgorzata Marjańska

http://www.w3.org/2001/XMLSchema#string

Ovidiu C Andronesi

http://www.w3.org/2001/XMLSchema#string

Tracy T Batchelor

http://www.w3.org/2001/XMLSchema#string

P2860

A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

An integrated genomic analysis of human glioblastoma multiforme

IDH1 and IDH2 mutations in gliomas

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

3D GABA imaging with real-time motion correction, shim update and reacquisition of adiabatic spiral MRSI

MGMT gene silencing and benefit from temozolomide in glioblastoma.

The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.

P304

1632-1641

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-15-0656

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Daniel P Cahill

Wolfgang Bogner

P577

2015-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26534967

http://www.w3.org/2001/XMLSchema#string

P932

4818725

http://www.w3.org/2001/XMLSchema#string